View Document Preview and Link Open Document File Size: 380,76 KB Share Result on Facebook
City Reference / / Company Pfizer Inc / Pfizer Netherlands / Appendix I. Communication Plan Pfizer Inc / / Event Product Issues / FDA Phase / / Facility Laboratory Abnormalities / Health-System Pharmacy / American College of Rheumatology / Managed Care Pharmacy / / IndustryTerm rheumatology healthcare providers / healthcare professionals / mycophenolic acid products / communication plan / healthcare providers / / MedicalCondition TB / opportunistic infections / Lymphoma / active infection / herpes zoster / Lymphoproliferative Disorder / Non-melanoma skin cancers / viral and other infections / rheumatoid arthritis / Arthritis &Rheumatism / skin cancer / active tuberculosis / active TB / Virus-associated post-transplant lymphoproliferative disorder / serious infections / non-melanoma skin cancer / lymphomas / severely active rheumatoid arthritis / localized infections / infection / invasive fungal infections / viral hepatitis / solid cancers / infections / Clinical Infectious Disease / Infectious disease / serious infection / tuberculosis / / MedicalTreatment renal transplant / / Organization Congress / American Society of Health System Pharmacists / Food and Drug Administration / FDA / American College of Rheumatology / Academy of Managed Care Pharmacy / / / Position Chief Medical Officer / Family Physician / Dear Pharmacist / nurse / physician / Pharmacist Letter IMPORTANT DRUG WARNING Dear Pharmacist / / Product The XELJANZ Medication / cyclosporine / azathioprine / XELJANZ Medication / Medication Guide The Medication / XELJANZ® (TOFACITINIB) / XELJANZ / response / / PublishedMedium The XELJANZ Medication Guide / Annals of Internal Medicine / The Medication Guide / Annals of Emergency Medicine / American Family Physician / / URL www.XELJANZREMS.com / www.fda.gov/medwatch/report.htm / / SocialTag 
REMS Initial REMS Approval: [removed]Most Recent Modification: [removed]NDA 203,214 XELJANZ® (TOFACITINIB)